Amylyx Q2 product revenue $98.2M, net income $22.1M; CHMP re-examining MAA

Amylyx Pharmaceuticals, Inc.

2023-Q2 EPS reported $0.34 revenue$169,644,000

Net product revenue $98.2M in Q2 2023 (up from $71.4M in Q1); net income $22.1M ($0.31 diluted EPS).
Cash, equivalents and short-term investments $357.3M at June 30, 2023.
Phase 3 ORION trial of AMX0035 for PSP to start by year-end; ~600 participants planned.
CHMP re-examining negative opinion on AMX0035 MAA for ALS; final opinion expected fall 2023.
Five Canadian provinces now reimburse ALBRIOZA; broad public coverage expected by end of August.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Amylyx Pharmaceuticals, Inc. reported second quarter ended June 30, 2023 results: revenue $98.2 million, net income $22.1 million, EPS $0.31 on a fully diluted per share basis.

Period: second quarter ended June 30, 2023
Revenue: $98.2 million
Net income: $22.1 million
EPS: $0.31 on a fully diluted per share basis
Result: reported results

Exact text from the filing

in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results ˗ Second quarter 2023 product revenue of $98.2 million; demand and insurance coverage for RELYVRIO® in U.S. and ALBRIOZATM in Canada continued to grow ˗ Strong financial position supported by $22.1 million of net income during the

View on SEC.gov

Browse all earnings releases →

Amylyx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-041274

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.